AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

Canadian VC saw $7.86 billion invested across 592 deals in 2024, per the CVCA, buoyed by later-stage megadeals while seed ...

(NYSE: RNG) reported fourth-quarter earnings and revenue that topped analyst estimates, but shares fell 2.5% in after-hours trading as the comp ...

Lloyds surged on earnings outlook, Centrica rose despite profit slump, BAE fell on US defence cuts, and Ferrexpo tumbled.

AstraZeneca (AZN) is set to acquire U.S. biotech company FibroGen’s (FGEN) China unit for $160 million to expand its presence in the country.

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed ...

The healthcare industry faced uncertainty throughout 2024 due to a number of factors. However, there is reason for optimism ...

The Parnassus Growth Equity Fund returned 4.85% (net) for Q4 2024, underperforming the Russell 1000 Growth Index’s 7.07%.

The biggest fallers on the FTSE 100 were Schroders, down 12p to 371.6p, IAG, down 8.9p to 338.5p, AstraZeneca, down 256p to ...

Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch.

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...